Article: ABILIFY approved for adolescent patients with schizophrenia.(Industry News)

Article: FDA Approves Labeling for Use of Xenical(R) (orlistat) in ...
PR Newswire;  December 16, 2003 ;     614 words ... ... Now, with the first weight- loss medication approved by the FDA with labeling for use in the management of obese adolescents ... for a prescription weight-loss treatment. Approved by the FDA in April of 1999 as a weight-loss treatment for adults, there ...

Article: Video Feed: FDA Approves Labeling for Use of Xenical(R) ...
PR Newswire;  December 17, 2003 ;     689 words ... ... Now, with the first weight-loss medication approved by the FDA with labeling for use in the management of obese adolescents ... for a prescription weight-loss treatment. Approved by the FDA in April of 1999 as a weight-loss treatment for adults, there ...

Article: Atypical antipsychotic approved for treatment Of bipolar I ...
Internal Medicine News;  April 15, 2008 ;     700+ words ... ... treating schizophrenia in adolescents aged 13-17 years at that time.) Olanzapine (Zyprexa) remains under review at the FDA for treating schizophrenia and bipolar disorder in adolescents aged 13-17, and the drug is considered "approvable" for those ...

Article: FDA approves labeling for use of Xenical in ...
Biotech Business Week;  January 12, 2004 ;     700+ words ...2004 JAN 12 - (NewsRx.com & NewsRx.net) -- Roche announced that the U.S. Food and Drug Administration has approved labeling for use of the prescription weight-loss medication Xenical (orlistat) in the management of obese adolescents ages 12 to 16 years. This is the first approval of its kind

Article: FDA Approves Labeling for Use of Xenical(R) (orlistat) in ...
PR Newswire;  December 15, 2003 ;     700+ words ...NUTLEY, N.J., Dec. 15 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration has approved labeling for use of the prescription weight-loss medication Xenical(R) (orlistat) in the management of obese adolescents ages 12 to 16 years. This is the first approval of its kind

Article: U.S. Food and Drug Administration Approves ABILIFY(R) ...
PR Newswire;  November 6, 2007 ;     700+ words ... ... Food and Drug Administration (FDA) approved the supplemental ... symptoms of schizophrenia. The FDA first approved ABILIFY for ... November 15, 2002. "Until now, FDA-approved treatment options for adolescent patients with schizophrenia were limited ...

Article: SEROQUEL Studied in Adolescent Patients with ...
PR Newswire;  October 12, 2001 ;     700+ words ... ... constant from baseline to discharge. Lastly, none of the patients exhibited significant weight gain (>7% as defined by the FDA standard) over the course of the study. Reported adverse events were generally mild to moderate and included somnolence, agitation ...